B. Metzler seel. Sohn & Co. AG Lowers Holdings in Thermo Fisher Scientific Inc. $TMO

B. Metzler seel. Sohn & Co. AG cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 21.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 454,402 shares of the medical research company's stock after selling 126,888 shares during the quarter. Thermo Fisher Scientific accounts for 2.0% of B. Metzler seel. Sohn & Co. AG's investment portfolio, making the stock its 12th largest position. B. Metzler seel. Sohn & Co. AG owned approximately 0.12% of Thermo Fisher Scientific worth $227,819,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of TMO. North Dakota State Investment Board purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $7,505,000. BlackRock Inc. purchased a new stake in shares of Thermo Fisher Scientific during the second quarter worth approximately $15,501,867,000. German American Bancorp Inc. purchased a new position in Thermo Fisher Scientific in the 2nd quarter valued at $4,920,000. Hudson Value Partners LLC increased its stake in Thermo Fisher Scientific by 24.9% in the 2nd quarter. Hudson Value Partners LLC now owns 16,653 shares of the medical research company's stock valued at $8,349,000 after buying an additional 3,317 shares during the period. Finally, Clearstead Trust LLC purchased a new position in Thermo Fisher Scientific during the 2nd quarter worth $3,779,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael D. Shafer sold 25,500 shares of the business's stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president directly owned 20,994 shares in the company, valued at $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 275 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $627.05, for a total transaction of $172,438.75. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company's stock, valued at $77,707,171.25. The trade was a 0.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 73,768 shares of company stock valued at $44,122,820 over the last quarter. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Price Performance

TMO stock opened at $608.33 on Thursday. The stock has a market capitalization of $224.93 billion, a price-to-earnings ratio of 32.72, a price-to-earnings-growth ratio of 2.51 and a beta of 0.85. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $647.00. The stock's fifty day simple moving average is $566.67 and its 200-day simple moving average is $513.61.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, topping the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm's revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period in the prior year, the business posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.11%.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on TMO shares. Wells Fargo & Company dropped their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating on the stock in a research report on Friday, May 8th. Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a report on Monday, July 6th. Sanford C. Bernstein initiated coverage on shares of Thermo Fisher Scientific in a report on Friday, June 26th. They issued a "market perform" rating and a $520.00 price target on the stock. Weiss Ratings upgraded Thermo Fisher Scientific from a "hold (c)" rating to a "hold (c+)" rating in a report on Friday, August 28th. Finally, Wolfe Research began coverage on Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an "outperform" rating and a $535.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $619.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source